The U.S. Food and Drug Administration on Wednesday revised the Emergency Use Authorization for Pfizer’s antiviral COVID-19 treatment Paxlovid, allowing pharmacists to prescribe the treatment, with limitations.
Paxlovid is authorized for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients 12 years old and older who are at high risk for progression to severe COVID-19, including hospitalization or death.
